MMA · Mixed Martial Arts Group Limited

This agreement represents a strategically significant, high-margin commercial expansion for MMA.INC into the rapidly growing peptide therapeutics and recovery market—without capital investment. The structure directly monetizes MMA’s existing scale: approximately 530,000 user profiles, 75,000+ active students, and 800+ verified gyms across 22 countries provide a ready-made, highly engaged distribution channel. The 50/50 revenue share in Year 1 incentivizes rapid co-commercialization, while the shift to 25% thereafter establishes a sustainable, long-term income stream aligned with customer lifetime value. Critically, the partnership leverages a key industry inflection point—increasing regulatory scrutiny is driving demand toward compliant, U.S.-manufactured, third-party tested peptide providers, positioning Precision as a differentiated supplier and MMA as a trusted gateway to its community. Management explicitly frames this as establishing an 'entirely new commercial vertical' intersecting recovery therapeutics, longevity, and regulated commercialization—underscoring its centrality to MMA.INC’s broader strategy of building a vertically integrated participation platform spanning training, technology, recovery, wellness, and performance optimization. The absence of upfront costs, exclusivity, and embedded tail rights mitigate execution risk and enhance durability of the revenue stream.